BMS-986020   Click here for help

GtoPdb Ligand ID: 9498

Synonyms: am-152 | AM152 | AP-3152 free acid
Compound class: Synthetic organic
Comment: BMS-986020 is an investigational lysophosphatidic acid 1 (LPA1) receptor antagonist [2]. It is claimed as Compound 1-1 in patent WO2010141768 [1], and this document contains extensive in vitro characterisation data and records in vivo anti-fibrotic efficacy in various animal models of fibrosis.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 101.66
Molecular weight 482.18
XLogP 6.82
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(OC(c1ccccc1)C)Nc1c(C)noc1c1ccc(cc1)c1ccc(cc1)C1(CC1)C(=O)O
Isomeric SMILES O=C(O[C@@H](c1ccccc1)C)Nc1c(C)noc1c1ccc(cc1)c1ccc(cc1)C1(CC1)C(=O)O
InChI InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1
InChI Key GQBRZBHEPUQRPL-LJQANCHMSA-N
No information available.
Summary of Clinical Use Click here for help
BMS-986020 has completed Phase 2 clinical trial for treating idiopathic pulmonary fibrosis. Results from NCT01766817) were reported in late 2017 [3]. The study was terminated early because of hepatotoxicity issues. BMS-986020 retains its FDA Orphan Drug designation that was granted in 2011 for the treatment of idiopathic pulmonary fibrosis (link to FDA Orphan Drug Designation record here).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Activation of the LPA1 receptor by LPA has been implicated in a number of disease processes, including tissue fibrosis. LPA1 receptor antagonists have displayed efficacy in a wide range of preclinical fibrosis models, including lung, skin, eye, liver and kidney.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01766817 Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis Phase 2 Interventional Bristol-Myers Squibb